Objective: To assess health-related quality of life and associated factors in patients treated with atypical antipsychotics, as well as to determine utility values using the EuroQol-5D-3L instrument. Methods: A cross-sectional study was conducted at a state-run pharmacy in the Brazilian National Health System. Individuals were included if they were using a single atypical antipsychotic and completed the EuroQol-5D-3L. Sociodemographic, behavioral, and clinical data were collected. The dependent variable was the EuroQol-5D-3L utility score. Associations between the independent variables and the dependent variable were analyzed in a multiple linear regression model. Results: A total of 394 patients were included, and their mean utility score was 0.664±0.232. Patients treated with clozapine had the highest mean score (0.762 [0.202]), followed by olanzapine (0.687 [0.230]), risperidone (0.630 [0.252]), ziprasidone (0.622 [0.234]), and quetiapine (0.620 [0.243]). The following variables were related to higher utility scores: income, employment, clozapine use, no illicit psychoactive substance use, no suicide attempts, and no comorbidities. Conclusion: Evaluating health-related quality of life differences in the available atypical antipsychotics can facilitate the choice of treatment, improve health outcomes, and ensure rational prescriptions.

中文翻译：

---

非典型抗精神病药物治疗患者的健康相关生活质量

目的：评估接受非典型抗精神病药物治疗的患者的健康相关生活质量和相关因素，并使用 EuroQol-5D-3L 仪器确定效用值。方法：在巴西国家卫生系统的一家国营药房进行横断面研究。使用单一非典型抗精神病药并完成 EuroQol-5D-3L 的个人被包括在内。收集了社会人口学、行为学和临床数据。因变量是 EuroQol-5D-3L 效用评分。在多元线性回归模型中分析自变量和因变量之间的关联。结果：共纳入394例患者，平均效用评分为0.664±0.232。接受氯氮平治疗的患者平均得分最高 (0.762 [0.202])，其次是奥氮平 (0.687 [0.230])、利培酮 (0.630 [0.252])、齐拉西酮 (0.622 [0.234]) 和喹硫平 (0.620 [0.243])。以下变量与更高的效用评分相关：收入、就业、氯氮平使用、无非法精神活性物质使用、无自杀企图和无合并症。结论：评估现有非典型抗精神病药物的健康相关生活质量差异可以促进治疗选择、改善健康结果并确保合理处方。